公开(公告)号：US20130102977A1

公开(公告)日：2013-04-25

申请号：US13678064

申请日：2012-11-15

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yasuko MATSUMURA ,  Kazuhiro FUKUSHIMA

IPC: A61K31/045 ,  A61F9/00

CPC classification number: A61K31/045 ,  A61F9/0061 ,  A61K9/0046 ,  A61K31/125 ,  A61K31/717 ,  A61K31/721 ,  A61K31/74

Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.

Abstract translation: 本发明提供了一种眼用组合物，其在佩戴隐形眼镜期间稳定了泪膜，防止眼睛干涩，赋予使用感觉，非常方便，没有被误用的风险，并且在制造过程中显示出高效率。 更具体地说，本发明提供一种用于隐形眼镜的润湿溶液 - 滴眼剂，其包括（A）一种或多种选自纤维素基聚合物，乙烯基类聚合物，聚乙二醇和葡聚糖的成员; 和（B）萜类化合物。

公开(公告)号：US12296038B2

公开(公告)日：2025-05-13

申请号：US17279296

申请日：2019-09-25

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yu Kitaoka ,  Mariko Iwai ,  Sho Yamashina

IPC: A61K8/67 ,  A61K8/34 ,  A61Q19/00

Abstract: Provided is a very stable topical composition. A topical composition is prepared that contains (A) from 1 to 40% by mass of at least one type selected from the group consisting of ascorbic acid and salts of ascorbic acid; (B) at least 20% by mass of a diol having three carbon atoms; (C) at least one type selected from the group consisting of tocopherol, salts of tocopherol, and derivatives of tocopherol; and (D) water, wherein the mass ratio of component (D) to component (A) is from 0.5 to 5.0 and the topical composition includes less than 20% by mass of glycol ether.

公开(公告)号：US20250041170A1

公开(公告)日：2025-02-06

申请号：US18709382

申请日：2022-11-22

Applicant: THE MENTHOLATUM COMPANY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiaki KAWAGUCHI

IPC: A61K8/02 ,  A61K8/34 ,  A61K8/63 ,  A61K8/81 ,  A61K8/92 ,  A61Q19/00

Abstract: To provide an oil-based solid composition for external use having excellent stability. An oil-based solid composition for external use is prepared that comprises: (A) an oily component with a melting point of 55° C. or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer.

公开(公告)号：US20230321058A1

公开(公告)日：2023-10-12

申请号：US17719078

申请日：2022-04-12

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Yasuko Matsumura

IPC: A61K31/4402 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/08 ,  A61K47/10 ,  A61K31/196 ,  A61K31/436 ,  A61K33/30 ,  A61K47/02 ,  A61K47/38

CPC classification number: A61K31/4402 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/08 ,  A61K47/10 ,  A61K31/196 ,  A61K31/436 ,  A61K33/30 ,  A61K47/02 ,  A61K47/38

Abstract: The first aspect of the present invention relates to an ophthalmic composition comprising (A) one or more kinds selected from the group consisting of terpenoid, a tocopherol, and a benzyl ammonium compound and a salt thereof, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.
The second aspect of the present invention relates to an ophthalmic composition comprising (A2) a surface active component and (B2) a buffer, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.

公开(公告)号：US20230032293A1

公开(公告)日：2023-02-02

申请号：US17881413

申请日：2022-08-04

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Kotoe Tamada

IPC: A61K35/28 ,  A61P9/10 ,  A61K9/06 ,  A61K9/08 ,  A61K38/36 ,  A61K38/48 ,  A61K9/12 ,  A61K9/10 ,  A61P9/00 ,  A61K38/00 ,  A61P27/02 ,  A61P43/00

Abstract: Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.

公开(公告)号：US20220401300A1

公开(公告)日：2022-12-22

申请号：US17770302

申请日：2019-10-21

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Naohiro Ikeda ,  Keita Kawai

IPC: A61J1/06 ,  B65D1/09

Abstract: The present invention is a resin container in which an inner wall surface of a container body includes a cyclic olefin copolymer, and a diameter upstream of an outlet of the container body ranges from 0.5 mm to 8.0 mm.

公开(公告)号：US20220133677A1

公开(公告)日：2022-05-05

申请号：US17498147

申请日：2021-10-11

Applicant: The Mentholatum Company ,  ROHTO Pharmaceutical Co., Ltd.

Inventor： Yoshiaki KAWAGUCHI ,  Tammam ALAMA

IPC: A61K31/325 ,  A61K9/00 ,  A61K9/06

Abstract: Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

公开(公告)号：US11253550B2

公开(公告)日：2022-02-22

申请号：US16490777

申请日：2018-02-22

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yui Ueno ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61P1/16

Abstract: The purpose of the present invention is to provide a novel therapeutic agent for liver disease. The present invention is a mesenchymal stem cell characterized by high expression of the Tissue Factor Pathway Inhibitor (TFPI). It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. Moreover, the present invention includes a therapeutic agent for liver disease containing the mesenchymal stem cell.

公开(公告)号：US10761087B2

公开(公告)日：2020-09-01

申请号：US16063047

申请日：2016-12-16

Applicant: Link Genomics, Inc. ,  ROHTO Pharmaceutical Co., Ltd.

Inventor： Shinichiro Niwa ,  Dai Ogura ,  Hidemi Mizunuma ,  Yoko Arai ,  Takahiro Kurose ,  Yoshihiro Takai ,  Yoko Mitsuguchi ,  Mariyo Moriya

IPC: G01N33/50 ,  A61K31/436 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/421 ,  A61K31/426 ,  A61K31/47 ,  A61K31/41 ,  A61K45/00 ,  A61P27/02 ,  A61K45/06

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

公开(公告)号：USD829555S1

公开(公告)日：2018-10-02

申请号：US29581602

申请日：2016-10-20

Applicant: Rohto Pharmaceutical Co., Ltd.

Designer： Shigehiko Kokubo